Form 4: TYRA CMO Granted 200,000 Stock Options

Tyra Biosciences' Chief Medical Officer, Douglas J. Warner, was granted 200,000 stock options with a $10.75 exercise price and a 10-year expiration.

Summary

• Douglas J. Warner, Chief Medical Officer and Director of Tyra Biosciences, Inc. (TYRA), was granted 200,000 stock options.
• The options have an exercise price of $10.75 per share.
• The options expire on August 6, 2035.
• Vesting schedule: 25% of the shares subject to the option shall vest on August 7, 2026, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, contingent on continuous service to the Issuer through each vesting date.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a positive sign for executive retention and alignment with shareholder interests, indicating confidence in the company's future. It's a standard compensation practice.

Positives

• Granting of stock options to a key executive like the Chief Medical Officer aligns their interests with shareholders, incentivizing long-term performance and retention.
• The 10-year expiration period provides a long-term incentive for the executive.

Negatives

• Potential for dilution if all options are exercised, though this is a standard aspect of equity compensation.

Future Outlook

The vesting schedule indicates a long-term incentive plan for the Chief Medical Officer, with initial vesting occurring one year after the grant date and subsequent monthly vesting over the following three years, contingent on continuous service.

Industry Context

Equity compensation, such as stock option grants, is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key scientific and executive talent, aligning their long-term interests with company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of 200,000 stock options to a Chief Medical Officer is a significant equity award, typical for a growth-stage biotechnology company like Tyra Biosciences, Inc.
• Such grants are competitive with similar roles at companies like Mirati Therapeutics or Blueprint Medicines, aiming to secure top-tier talent in a highly competitive sector.
• The 10-year term and four-year vesting schedule (one-year cliff, then monthly) are standard for executive equity incentives in the biotech industry.

Related Party Transactions

• Grant of 200,000 stock options to Douglas J. Warner, Chief Medical Officer and Director, which constitutes a transaction with a related party as part of executive compensation.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through executive incentive, but also potential for minor dilution upon exercise.
• Employees: May signal stability and commitment to key leadership, potentially boosting morale.

Next Steps

• Continued service of Douglas J. Warner to the Issuer.
• Vesting of 25% of options on August 7, 2026.
• Monthly vesting of remaining options thereafter.

Key Dates

Recommendation

This filing details a routine executive compensation event (stock option grant) which is a standard practice for public companies to incentivize and retain key personnel. It does not provide new information regarding the company's financial performance, strategic direction, or operational results that would warrant a change in investment recommendation. Investors should continue to monitor the company's core business developments and financial reports.

Keywords

Tyra Biosciences, TYRA, Stock Options, Equity Compensation, SEC Form 4, Chief Medical Officer, Executive Compensation, Biotechnology